ESMO 2025 preview: the Phase III pivots to watch
If recent top-line reads deliver on the big stage, this week's ESMO 2025 could re-draw standards across breast, genitourinary, gynaecologic and colorectal cancers—powered by three recurring themes: ADCs stepping earlier, radioligand therapy moving upstream, and immuno-oncology showing life beyond metastatic niches.
Breast cancer: Enhertu takes aim at adjuvant T-DM1
AstraZeneca/Daiichi Sankyo’s DESTINY-Breast05—the first head-to-head Phase III pitting trastuzumab deruxtecan (Enhertu) versus ado-trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer with residual disease post-neoadjuvant—has already read out positively on invasive disease-free survival (IDFS) at interim. The program has a Presidential Symposium slot, with LBA1 flagged by the company for October 18, alongside the neoadjuvant DESTINY-Breast11—clear signalling of regulatory intent. AstraZeneca
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze